Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Director | February 04, 2026 | February 05, 2026 |
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 06, 2021 | May 24, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eikon Therapeutics, Inc.
Report date February 04, 2026 · Filed February 05, 2026
This filing explicitly reported no securities owned.
Nurix Therapeutics, Inc.
Report date May 06, 2021 · Filed May 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.38 · Expires 2031-05-05 | Direct | 17,500 |
Reported balance
After 2021-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-06 · Grant · Acquired 17,500 · Balance 17,500 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. F2: The Reporting Person is a partner of The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP") and Ponoi Capital II, LP ("Ponoi II LP," and together with TCG II LP and Ponoi LP, the "Funds"), among other entities. Under the partnership agreements of the Funds, the Reporting Person is deemed to hold the stock option for the economic benefit of the Funds. The Funds may be deemed indirect beneficial owners of the stock option. The Reporting Person disclaims beneficial ownership of the stock option except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
F2: The Reporting Person is a partner of The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP") and Ponoi Capital II, LP ("Ponoi II LP," and together with TCG II LP and Ponoi LP, the "Funds"), among other entities. Under the partnership agreements of the Funds, the Reporting Person is deemed to hold the stock option for the economic benefit of the Funds. The Funds may be deemed indirect beneficial owners of the stock option. The Reporting Person disclaims beneficial ownership of the stock option except to the extent of his pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LogicBio Therapeutics, Inc.
Report date November 16, 2022 · Filed November 17, 2022
Section 16 reporting ended · disclosed 2022-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 1
1 source rowRow 1 · 2022-11-16 · Disposition to issuer · Disposed 22,333 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the "Merger Agreement"), by and among LogicBio Therapeutics, Inc. (the "Company"), Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.73 · Expires 2027-11-02 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-16 · Disposition to issuer · Disposed 44,508 · Balance 0 F3: At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. F2: The options were fully vested as of June 19, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2032-06-17 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-16 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. F4: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the "Merger Agreement"), by and among LogicBio Therapeutics, Inc. (the "Company"), Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes.
F2: The options were fully vested as of June 19, 2021.
F3: At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.
F4: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 16, 2022 Filed Nov 17, 2022 21:04 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | Disposition to issuerStock Option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $0.38 | Not disclosed |
DisclosureSEC source: 0000899243-22-036292 · doc4.xml · derivative · entry 3 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2032-06-17 F3 · price: At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. F4 · derivative.exercise_date: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 21:04 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | Disposition to issuerStock Option (right to buy) · Derivative | 44,508 | Not disclosed Strike: $0.73 | Not disclosed |
DisclosureSEC source: 0000899243-22-036292 · doc4.xml · derivative · entry 2 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,508 shares Expires 2027-11-02 F3 · price: At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. F2 · derivative.exercise_date: The options were fully vested as of June 19, 2021. Read SEC document |
| November 16, 2022 Filed Nov 17, 2022 21:04 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | Disposition to issuerCommon Stock | 22,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-036292 · doc4.xml · nonDerivative · entry 1 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the "Merger Agreement"), by and among LogicBio Therapeutics, Inc. (the "Company"), Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 08:00 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-22-038232 · doc4.xml · derivative · entry 1 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-17 F1 · shares: The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan, as provided under the Company's current non-employee director compensation policy. F2 · derivative.exercise_date: The options will vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 20:00 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001209191-21-040428 · doc4.xml · derivative · entry 1 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-11 F1 · derivative.exercise_date: The options were granted by the Issuer pursuant to its 2018 Equity Incentive Plan as provided under the Company's compensation policy for non-employee directors. All of the options will vest and become exercisable on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2022 annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer through the vesting date. Read SEC document |
| May 06, 2021 Filed May 24, 2021 23:48 UTC | Nurix Therapeutics, Inc. NRIX · Entity 1156 | GrantDirector Stock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $27.38 | $0.00 |
DisclosureSEC source: 0001209191-21-035535 · doc4.xml · derivative · entry 1 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-05-05 F1 · derivative.exercise_date: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 6, 2022, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. F2 · ownership.direct: The Reporting Person is a partner of The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP") and Ponoi Capital II, LP ("Ponoi II LP," and together with TCG II LP and Ponoi LP, the "Funds"), among other entities. Under the partnership agreements of the Funds, the Reporting Person is deemed to hold the stock option for the economic benefit of the Funds. The Funds may be deemed indirect beneficial owners of the stock option. The Reporting Person disclaims beneficial ownership of the stock option except to the extent of his pecuniary interest therein. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 19:00 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | Exercise / conversionRestricted Stock Units · Derivative | 3,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-000519 · doc4.xml · derivative · entry 2 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,298 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company"). F2 · derivative.exercise_date: All of the RSUs vested on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan. F2 · derivative.expiration_date: All of the RSUs vested on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 19:00 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | Exercise / conversionCommon Stock | 3,298 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-000519 · doc4.xml · nonDerivative · entry 1 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,298 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company"). Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 20:00 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantRestricted Stock Units · Derivative | 3,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-038661 · doc4.xml · derivative · entry 2 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,298 Underlying: Common Stock · 3,298 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: All of the RSUs will vest on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan. F3 · derivative.expiration_date: All of the RSUs will vest on January 1, 2021, subject to the terms and conditions of the award and the Company's 2018 Plan. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 20:00 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.96 | $0.00 |
DisclosureSEC source: 0001209191-20-038661 · doc4.xml · derivative · entry 1 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-19 F1 · derivative.exercise_date: All of the options will vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of LogicBio Therapeutics, Inc. (the "Company") 2021 Annual Meeting of Stockholders, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan (the "2018 Plan"). Read SEC document |
| December 19, 2019 Filed Dec 20, 2019 20:00 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 10,869 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001209191-19-061663 · doc4.xml · derivative · entry 1 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,869 Underlying: Common Stock · 10,869 shares Expires 2029-12-19 F1 · derivative.exercise_date: 100% vests on the earlier of 7/15/2020 or the 2020 Annual Meeting of Stockholders. Read SEC document |
| October 18, 2018 Filed Oct 22, 2018 21:19 UTC | LogicBio Therapeutics, Inc. LOGC · Entity 122292 | GrantStock Option (right to buy) · Derivative | 24,102 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000899243-18-027225 · doc4.xml · derivative · entry 1 Chen Leon · CIK 0001752432 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,102 Underlying: Common Stock · 24,102 shares Expires 2028-10-17 F1 · derivative.exercise_date: The option becomes exercisable in equal installments on each of the first three anniversaries of the grant date, October 18, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.